Pulmonary arterial hypertension in patients treated by dasatinib.

Background: The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib.

Methods And Results: This study was designed to describe incident cases of dasatinib-associated PH reported in the French PH registry.